RECRUITINGINTERVENTIONAL

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia

About This Trial

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Who May Be Eligible (Plain English)

Who May Qualify: Subjects - African American - Patients with sickle cell anemia - 18 years old or older Control - African American healthy controls - 18 years of age or older Who Should NOT Join This Trial: 1. Pregnancy, 2. Known hypertension, 3. Hemodialysis and active obstructive sleep apnea requiring treatment. 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: Subjects * African American * Patients with sickle cell anemia * 18 years old or older Control * African American healthy controls * 18 years of age or older Exclusion Criteria: 1. Pregnancy, 2. Known hypertension, 3. Hemodialysis and active obstructive sleep apnea requiring treatment. 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Treatments Being Tested

DIETARY_SUPPLEMENT